Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis Company anticipates topline results of RESOLVE-1 study in the summer of 2020Systemic sclerosis (SSc) is a chronic, rare systemic autoimmune disease affecting approximately 200,000 people in the U.S.,...